Literature DB >> 12598414

Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents.

Nina Isoherranen1, Boris Yagen, José H Woodhead, Ofer Spiegelstein, Simcha Blotnik, Karen S Wilcox, Richard H Finnell, Gregory D Bennett, H Steve White, Meir Bialer.   

Abstract

1. Propylisopropyl acetamide (PID) is a new chiral amide derivative of valproic acid. The purpose of this study was to evaluate the anticonvulsant activity of PID in rodent models of partial, secondarily generalized and sound-induced generalized seizures which focus on different methods of seizure induction, both acute stimuli, and following short-term plastic changes as a result of kindling, and to assess enantioselectivity and enantiomer-enantiomer interactions in the pharmacokinetics and pharmacodynamics of racemic PID and its pure enantiomers in rodents. 2. Anticonvulsant activity of (S)-PID, (R)-PID and racemic PID was evaluated in the 6 Hz psychomotor seizure model in mice, in the hippocampal kindled rat, and in the Frings audiogenic seizure susceptible mouse. The pharmacokinetics of (S)-PID and (R)-PID was studied in mice and rats. 3. In mice (S)-PID, (R)-PID and racemic PID were effective in preventing the 6 Hz seizures with (R)-PID being significantly (P < 0.05) more potent (ED(50) values 11 mg kg(-1), 46 mg kg(-1) and 57 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively) than (S)-PID (ED(50) values 20 mg kg(-1), 73 mg kg(-1) and 81 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively). (S)-PID, (R)-PID and racemic PID also blocked generalized seizures in the Frings mice (ED(50) values 16 mg kg(-1), 20 mg kg(-1) and 19 mg kg(-1) respectively). 4. In the hippocampal kindled rat a dose of 40 mg kg(-1) of (R)- and (S)-PID prevented the secondarily generalized seizure, whereas racemic PID also blocked the expression of partial seizures following an i.p. dose of 40 mg kg(-1). Racemic PID also significantly increased the seizure threshold in this model. 5. Mechanistic studies showed that PID did not affect voltage-sensitive sodium channels or kainate-, GABA- or NMDA- evoked currents. 6. The pharmacokinetics of PID was enantioselective following i.p. administration of individual enantiomers to mice, with (R)-PID having lower clearance and longer half-life than (S)-PID. In rats and mice, no enantioselectivity in the pharmacokinetics of PID was observed following administration of the racemate, which may be due to enantiomer-enantiomer interaction. 7. This study demonstrated that PID has both enantioselective pharmacokinetics and pharmacodynamics. The better anticonvulsant potency of (R)-PID in comparison to (S)-PID may be due to its more favorable pharmacokinetic profile. The enhanced efficacy of the racemate over the individual enantiomers in the kindled rat may be explained by a pharmacokinetic enantiomer-enantiomer interaction in rats. This study also showed the importance of studying the pharmacokinetics and pharmacodynamics of chiral drugs following administration of the individual enantiomers as well as the racemic mixture.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12598414      PMCID: PMC1573693          DOI: 10.1038/sj.bjp.0705076

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission.

Authors:  James F Otto; Matthew M Kimball; Karen S Wilcox
Journal:  Mol Pharmacol       Date:  2002-04       Impact factor: 4.436

2.  Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug.

Authors:  N Isoherranen; J H Woodhead; H S White; M Bialer
Journal:  Epilepsia       Date:  2001-07       Impact factor: 5.864

3.  Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test.

Authors:  W C BROWN; D O SCHIFFMAN; E A SWINYARD; L S GOODMAN
Journal:  J Pharmacol Exp Ther       Date:  1953-03       Impact factor: 4.030

4.  Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats.

Authors:  W Löscher; E Reissmüller; U Ebert
Journal:  Epilepsy Res       Date:  2000-06       Impact factor: 3.045

5.  Testing for the equality of area under the curves when using destructive measurement techniques.

Authors:  A J Bailer
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

6.  Estimation of variance for AUC in animal studies.

Authors:  J Yuan
Journal:  J Pharm Sci       Date:  1993-07       Impact factor: 3.534

7.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

8.  Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs.

Authors:  M Bialer
Journal:  J Control Release       Date:  1999-11-01       Impact factor: 9.776

9.  The dihydropyridine nitrendipine reduces N-methyl-D-aspartate (NMDA)-evoked currents of rodent cortical neurons through a direct interaction with the NMDA receptor-associated ion channel.

Authors:  G A Skeen; H S White; R E Twyman
Journal:  J Pharmacol Exp Ther       Date:  1994-10       Impact factor: 4.030

10.  Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats.

Authors:  W Löscher; D Hönack
Journal:  Eur J Pharmacol       Date:  1993-03-02       Impact factor: 4.432

View more
  6 in total

Review 1.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

Review 2.  Key factors in the discovery and development of new antiepileptic drugs.

Authors:  Meir Bialer; H Steve White
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 3.  Valproic Acid: second generation.

Authors:  Meir Bialer; Boris Yagen
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

4.  Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.

Authors:  Nina Isoherranen; H Steve White; Brian D Klein; Michael Roeder; José H Woodhead; Volker Schurig; Boris Yagen; Meir Bialer
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

Review 5.  Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?

Authors:  Aaron C Gerlach; Jeffrey L Krajewski
Journal:  Pharmaceuticals (Basel)       Date:  2010-09-01

Review 6.  Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile.

Authors:  Manish Kumar Mishra; Samiksha Kukal; Priyanka Rani Paul; Shivangi Bora; Anju Singh; Shrikant Kukreti; Luciano Saso; Karthikeyan Muthusamy; Yasha Hasija; Ritushree Kukreti
Journal:  Molecules       Date:  2021-12-24       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.